. 2024 Oct 5;10:186. doi: 10.1038/s41531-024-00791-2

Table 3.

summary of four different studies that investigated the potential of using exosomal miRNAs as biomarkers for diagnosis

Study	PD group(n)	Control(n)	Exosome source	RNA extraction	RNA identification	miRNAs expression	Exosomal miRNAs	Accuracy of diagnosis(AUC)
Gui et al. ¹¹⁵	47	27	CSF	Qiagen miRNeasy Serum/Plasma Kit	TaqMan Real-Time PCR	Upregulated	ex- miR-10a-5p	0.900
							ex-miR-153	0.780
							ex-miR-409-3p	0.970
						Downregulated	ex-miR-1	0.920
						Downregulated	ex-miR-19b-3p	0.705
Cao et al. ¹⁰⁵	109	40	Serum	miRNeasy Mini Kit	RT-PCR followed by qPCR	Upregulated	miR-24	0.908
						Upregulated	miR-195	0.697
						Downregulated	miR-19b	0.753
Yao et al. ¹⁴⁷	52	48	Plasma	Exosomal RNA and Protein Extraction kit	RT-qPCR	Upregulated	ex-miR-331-5p	0.849
Yao et al. ¹⁴⁷	52	48	Plasma	Exosomal RNA and Protein Extraction kit	RT-qPCR	Downregulated	ex-miR-505	0.898
Barbagallo et al. ¹⁴⁸	30	30	Serum	miRNeasy Mini-Kit (Qiagen)	TaqMan RT-PCR	Upregulated	ex-let-7d,	0.753
							ex-miR-22	0.845
							ex- miR-23a	0.869
							ex-miR-24	0.779
							ex- miR-142-3p	0.783
							and ex-miR-222	0.816

miR/miRNA microRNA, PD Parkinson’s disease, AUC area under the curve, CSF cerebrospinal fluid, RT-qPCR quantitative reverse transcription polymerase chain reaction.